Literature DB >> 11516856

Definitive intraoperative very high-dose radiotherapy for localized osteosarcoma in the extremities.

N Oya1, M Kokubo, T Mizowaki, Y Shibamoto, Y Nagata, K Sasai, Y Nishimura, T Tsuboyama, J Toguchida, T Nakamura, M Hiraoka.   

Abstract

PURPOSE: To evaluate the outcome and adverse effects in patients with osteosarcoma treated with very high-dose definitive intraoperative radiotherapy (IORT), with the intention of saving the affected limb. METHODS AND MATERIALS: Thirty-nine patients with osteosarcoma in their extremities were treated with definitive IORT. The irradiation field included the tumor plus an adequate wide margin and excluded the major vessels and nerves. Forty-five to 80 Gy of electrons or X-rays were delivered. The median follow-up of the surviving patients was 124 months.
RESULTS: The cause-specific and relapse-free 5-year survival rate was 50% and 43%, respectively. Distant metastasis developed in 23 patients; 19 died and 4 were alive for >10 years. Nine local recurrences were found 4-29 months after IORT in the affected limb. No radiation-induced skin reaction or nerve palsy was observed in the patients treated with X-rays. Experiments using phantoms also confirmed that the scatter dose was below the toxic level in the IORT setting with X-rays.
CONCLUSIONS: Very high-dose definitive IORT combined with preventive nailing and chemotherapy appeared to be a promising quality-of-life-oriented alternative to treating patients with osteosarcomas in the extremities, although the problem of recurrences from the surrounding unirradiated soft tissue remains to be solved.

Entities:  

Mesh:

Year:  2001        PMID: 11516856     DOI: 10.1016/s0360-3016(01)01603-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.

Authors:  Claudia Blattmann; Susanne Oertel; Daniela Schulz-Ertner; Stefan Rieken; Sabine Haufe; Volker Ewerbeck; Andreas Unterberg; Irini Karapanagiotou-Schenkel; Stephanie E Combs; Anna Nikoghosyan; Marc Bischof; Oliver Jäkel; Peter Huber; Andreas E Kulozik; Jürgen Debus
Journal:  BMC Cancer       Date:  2010-03-12       Impact factor: 4.430

2.  Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells.

Authors:  Kozo Hosono; Yoshihiro Nishida; Warren Knudson; Cheryl B Knudson; Takahiro Naruse; Yoshitaka Suzuki; Naoki Ishiguro
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

3.  Use of irradiated autologous bone in joint sparing endoprosthetic femoral replacement tumor surgery.

Authors:  Sridhar Vijayan; William Bartlett; Robert Lee; Peter Ostler; Gordon W Blunn; Stephen R Cannon; Timothy Wr Briggs
Journal:  Indian J Orthop       Date:  2011-03       Impact factor: 1.251

4.  Mesenchymal stem cells with rhBMP-2 inhibits the growth of canine osteosarcoma cells.

Authors:  Rose Eli Grassi Rici; Dayane Alcântara; Paula Fratini; Cristiane Valverde Wenceslau; Carlos Eduardo Ambrósio; Maria Angelica Miglino; Durvanei Augusto Maria
Journal:  BMC Vet Res       Date:  2012-02-22       Impact factor: 2.741

5.  Understanding the potentiality of accelerator based-boron neutron capture therapy for osteosarcoma: dosimetry assessment based on the reported clinical experience.

Authors:  Silva Bortolussi; Ian Postuma; Nicoletta Protti; Lucas Provenzano; Cinzia Ferrari; Laura Cansolino; Paolo Dionigi; Olimpio Galasso; Giorgio Gasparini; Saverio Altieri; Shin-Ichi Miyatake; Sara J González
Journal:  Radiat Oncol       Date:  2017-08-15       Impact factor: 3.481

6.  Minimally invasive surgery using intraoperative electron-beam radiotherapy for the treatment of soft tissue sarcoma of the extremities with tendon involvement.

Authors:  Akihiko Matsumine; Masaya Tsujii; Tomoki Nakamura; Kunihiro Asanuma; Takao Matsubara; Takuya Kakimoto; Yuki Yada; Akinori Takada; Noriko Ii; Yoshihito Nomoto; Akihiro Sudo
Journal:  World J Surg Oncol       Date:  2016-08-12       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.